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Recent society guideline recommendations have lowered the threshold for initiation of statin therapy for the primary prevention of cardiovascular events, resulting in as many as 12.8 million new prescriptions for statin therapy. Most of these individuals do not have established CVD and the majority will never experience a cardiovascular event [1] . These recommendations occur in the context of recent data suggesting an association between statin therapy and type 2 diabetes (T2D) [2] . Although multiple large randomized trials demonstrated an average CVD benefit from statin therapy exceeding average harm from increased rate of T2D [3] , the U.S. Food and Drug Administration has required a warning regarding risk of T2D with statin therapy since February 2012. Just as risk stratification modalities such as the Pooled Cohort Equations and coronary artery 1 2 3 4 5 6 7 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55 calcium (CAC) scores have enabled targeting of statin therapy to those who are most likely to benefit, there is need for improved stratification of T2D risk among patients treated with statins. In this regard, hepatic lipid accumulation ("steatosis") has emerged as a weight-independent risk factor of poorer insulin sensitivity, subclinical atherosclerosis and a pro-inflammatory phenotypedfactors relevant to both T2D and CVD risk. Hepatic xray attenuationda well-validated computed tomographic (CT) marker of steatosis [4, 5] dis easily measured simultaneous with CAC score assessment. We hypothesized that the simultaneous measurement of both indices would provide an effective tool for identification of subgroups with greatest potential benefit and greatest risk of harm from statin therapy, thereby allowing for greater personalization of treatment.
We present results of a study that included 3153 individuals in the Multi-Ethnic Study of Atherosclerosis without T2D and not on statin therapy at study entry who underwent chest CT imaging at baseline study visit and subsequent follow-up for incident T2D and CVD events. We investigated the impact of liver fat on T2D and CVD risk independent of established clinical risk markers. Furthermore, we determined whether an approach guided by coronary artery calcium scoring and hepatic attenuation simultaneously might identify T2D risk in individuals on statin therapy for improved surveillance.
Methods

Study population
The MESA study design has been previously described in detail [6] . In brief, the MESA study enrolled 6814 individuals of diverse ethnicities (white, African American, Chinese American and Hispanic) from six American sites. MESA participants were free of cardiovascular disease (history of myocardial infarction, angina pectoris, prior revascularization, heart failure, atrial fibrillation, stroke, or peripheral arterial disease) at study onset. Derivation of our study cohort is shown in Supplemental Fig. 1 . The final cohort included 3153 individuals who underwent CT scanning with quantification of coronary artery calcium score and hepatic attenuation at Exam 1. Informed consent was obtained from all subjects and institutional review board approval was obtained.
Baseline demographics, history, medications, fasting blood glucose, and clinical examination were assessed at 5 clinic visits (Exams 1e5; between 2000 and 2011). Metabolic syndrome was adjudicated at each MESA visit by National Cholesterol Education Panel Adult Treatment Panel III guidelines [7] . Hypertension at Exam 1 was defined as systolic blood pressure ! 140 mmHg or diastolic blood pressure ! 90 mmHg or either self-reported history of hypertension or use of anti-hypertensive medication. Diabetes was defined by American Diabetes Association 2003 guidelines (defined by fasting glucose and/or treatment for diabetes) [8] . Individuals were followed for incident T2D (as defined above) as well as composite hard CVD events including myocardial infarction, resuscitated cardiac arrest, stroke (not including transient ischemic attacks) and death from coronary heart disease or stroke. Statin use was determined directly, as participants brought in their medication bottles to MESA clinic visits, and a technician recorded the medication name and strength. Intensity of statin therapy was graded based on a modified version of the classification in the 2013 ACC/AHA guidelines [9] (Supplemental Table 1 ).
Measurement of liver fat and coronary calcification
Measurement of liver attenuation has been previously described [10] . Briefly, liver attenuation was measured as the average intensity of two regions approximately 1 cm 2 each within the parenchyma of the right hepatic lobe, avoiding vascular structures and hepatic cysts. To assess the presence of a dose-response effect, we also categorized liver attenuation into quartiles corresponding to: 57, 57.5e62.5, 62.6e67.5 and !67.6 HU, respectively. We also used the previously validated threshold of 40 Hounsfield units (HU) to be a marker of significant hepatic steatosis [11] . Coronary artery calcium score was determined as described in prior MESA reports and categorized as 0, 1e100 and >100 [12] .
Statistical analysis
All variables were examined for normality and parametric or non-parametric tests were selected as appropriate. We compared baseline characteristics between those without statin prescriptions and those with incident statin use with KruskaleWallis, Fisher exact and chi-square tests for continuous, dichotomous and categorical variables, respectively. Two-sided P-values <0.05 were considered significant. All analyses were performed in SAS 9.4 (SAS Institute, Cary, NC) or R 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).
Survival analysis for diabetes
We estimated rates of incident diabetes per 10 person-years using Poisson regression, after confirming the absence of significant over-dispersion. We used a generalized additive model with Poisson regression to explore the non-linear relationship between liver attenuation and rate of incident diabetes. Using generalized linear models, we computed unadjusted rates across quartiles of liver attenuation, as well as rates adjusted for race, gender, family history of diabetes, total weekly intentional exercise, fasting glucose and C-reactive protein levels at exam 1. Age, BMI, waist circumference, systolic blood pressure, and serum HDL and triglycerides were entered as time-varying covariates at each MESA examination. We analyzed the impact of hepatic steatosis and statin treatment using a discrete-time Cox survival model, adjusting for time-varying and time-invariant covariates as in Poisson regression. If T2D and statin therapy occurred concurrently in the same MESA examination, T2D was not considered statinassociated. We assessed improvement in model fit with the global c 2 and Akaike information criterion (AIC), discrimination with the c-index and risk assessment with the net reclassification improvement (NRI) [13] . Confidence intervals for NRI were computed using bootstrapping. In order to further assess the impact of residual confounding, we constructed a logistic regression model for the initiation of statin therapy (c-index 0.77, 95% CI 0.75e0.79). We used the predicted probability of statin initiation as a propensity score. The Cox regression was then repeated [1] stratifying by deciles of the propensity score and [2] adjusting for the propensity score. Finally, we examined whether appropriateness of statin prescription was related to incident diabetes using a contemporary definition of appropriateness (>5% 10-year risk threshold for appropriateness by the pooled cohort equations or a calcium score !100).
Survival analysis for CVD endpoints
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Evaluation of competing risks from statin therapy
We divided the study population based on liver attenuation (quartile 1 vs quartiles 2e4). These two groups were subdivided based on calcium score (0, 1e100, >100). We used a Poisson regression of the entire study cohort to estimate the adjusted rate of incident diabetes per 10 person-years in each of the resulting six groups under two conditions: non-use and use of statins. We used unadjusted Poisson regression to estimate rates of incident hard CVD events per 10 person-years in each of the six groups. We estimated the potential reduction in CVD events by multiplying the observed hard CVD event rate by the 22% risk reduction observed in a recent meta-analysis [14] . This approach has been taken in prior work within MESA [12, 15] . These estimates of risk differences for diabetes and hard CVD events with and without statin treatment were then used to compute numbers needed to harm (NNH) and treat (NNT), respectively.
Results
Baseline characteristics, stratified by statin prescription
Baseline characteristics of the MESA study population are shown in Table 1 . Compared to participants who were not on statin therapy at baseline or in follow-up ("no statin" group; N ¼ 2237), individuals started on statin therapy after MESA Exam 1 were more likely to be older with greater baseline metabolic risk at baseline study visit (by body mass index, waist circumference, blood pressure, fasting glucose, C-reactive protein and metabolic syndrome diagnosis; all P < 0.01). The median coronary calcium score was slightly higher among those initiated on statin therapy (0 vs 1.6, P < 0.0001). Liver attenuation by CT was slightly lower in patients referred for statin therapy (63 vs. 62 HU; P ¼ 0.003). The racial and gender distribution was similar in both groups.
Liver fat is associated with incident T2D and reclassifies risk of T2D independent of clinical risk factors and statin use
A total 216 cases of incident T2D were diagnosed in 3153 patients (6.9%) at a median 9.1 years of follow-up (IQR 4.8e9.5 years) (Supplemental Table 2 ). The lowest quartile of hepatic attenuation (indicating the greatest degree of hepatic steatosis) was associated with a markedly increased risk of incident T2D (Fig. 1) . Notably, risk began to rise even above previously suggested thresholds for fatty liver of 40 HU (Fig. 2) . The greatest risk of incident T2D was among individuals who both received statin therapy at follow-up and were in lowest quartile of hepatic attenuation (Supplemental Fig. 2) .
In multivariable Cox survival analysis, the presence of a fatty liver (quartile 1 of hepatic attenuation; HR ¼ 2.06, 95% CI 1.52e2.79; P < 0.0001) was associated with incident T2D risk, independent of statin initiation, established clinical and metabolic risk factors ( Table 2 ). The addition of fatty liver significantly improved net reclassification (NRI ¼ 0.32, 95% CI 0.05e0.58) beyond statin use and clinical/metabolic risk factors. The favorable NRI was largely driven by the NRI among individuals who did not develop diabetes (NRI nonevents ¼ 0.41, 95% CI 0.37e0.44), indicating powerful negative predictive value. There was no effect modification of the association 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 between hepatic attenuation and T2D by age, gender, race, weight, waist circumference, BMI or statin use. We found similar results when a threshold of 40 HU was used to define a fatty liver. After multivariable adjustment, the relationship between statin therapy and incident diabetes was not altered by the intensity of statin therapy. When this analysis was repeated with propensitystratification or propensity-adjustment for statin initiation, nearly identical results were obtained. Finally, appropriateness of statin therapy was not associated with incident diabetes.
Coronary calcification and liver fat identify competing cardiovascular benefit and risks of statin treatment
At a median follow-up of 10.4 years (IQR 9.8e10.8 years), a total of 152 hard cardiovascular events (4.8%) were observed in the study population. While coronary artery calcium score was associated with CVD events at long-term follow-up similar to prior MESA results, hepatic attenuation was not associated with CVD, except in the intermediate calcium score stratum (CAC 1e100; Supplemental  Fig. 3 ). The distribution of calcium score was not different based on liver attenuation (Supplemental Fig. 4) .
We investigated whether hepatic attenuation and coronary artery calcification could be used jointly to balance T2D risk and CVD risk (Fig. 3) . In individuals with less liver fat (quartiles 2e4) and either zero or intermediate calcium score, the expected absolute CVD risk reduction from statin therapy is 0.5% and 1.0%, respectively, corresponding to number needed to treat with a statin (NNT) 218 and 103, respectively, to prevent one CVD event. Conversely, the expected absolute T2D risk increase from statin therapy is 1.5% and 1.6% for zero and intermediate calcium score, respectively, corresponding to number needed to harm for an incident case of T2D (NNH) 68 and 63, respectively. The expected absolute T2D risk increase was consistently higher (4.2e4.5%) and NNH [22e24] was consistently lower among individuals with a fatty liver (quartile 1), regardless of calcium score.
Among MESA participants with higher calcium score (CAC > 100) and less liver fat ("normal" liver), the expected absolute CVD risk reduction was 3.4%, corresponding to NNT to prevent one CVD event 29, which was lower than an absolute T2D risk increase of 1.5% (NNH for one additional T2D case 67). Conversely, among those with higher calcium score and a fatty liver, the expected absolute CVD risk reduction is 2.5% (NNT 40 for CVD prevention), compared to a 4.2% expected absolute T2D risk increase with statins (NNH 24 for an additional T2D case).
Discussion
Recent guideline updates have resulted in over 12 million American adults newly qualifying for statin therapy [1] . This expansion has brought to the forefront a debate over whether further expansion of statin therapy appropriately balances reduction in CVD risk with the potential for increased T2D associated with statin therapy. In this study, we have demonstrated that hepatic fatda metabolic marker reflecting systemic inflammation and insulin resistancedcan reclassify risk of T2D beyond traditional Importantly, risk of diabetes is increased even above previously described thresholds of 40 HU for fatty liver. Unadjusted incidence rate curves and 95% confidence intervals were computed with Poisson regression using a generalized additive model with a log link function. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 4   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 clinical risk factors and statin prescription. Importantly, hepatic fat improves risk assessment for T2D beyond variables included in validated diabetes risks scores [16] . Rates of incident T2D with statin therapy were greater among MESA participants with low hepatic attenuation (higher liver fat). Using coronary artery calcium score, a well-established marker of CVD risk [12] , we found that hepatic attenuation and CAC score stratify incident T2D and CVD risk in a largely separable manner. Among individuals with zero-tointermediate CAC score ( 100), CVD risk reduction with statin therapy was accompanied by a high risk of incident T2D, especially among those with a fatty liver. While MESA participants with higher CAC scores (>100) and lower liver fat had substantial CVD risk reduction with a modest risk of incident T2D, those with a fatty liver had CVD risk reduction (relative to incident T2D risks) with statin therapy. The primary clinical implication of these findings is that hepatic fat and coronary artery calcium scoredboth simultaneously attained in one non-contrast, low radiation dose CT scandcan identify individuals requiring greater surveillance for incident T2D while on clinically indicated statin therapy for primary CVD prevention. While it is clear that T2D and CVD are not clinically equivalent outcomes, this approach may serve to further refine the risk/benefit calculus for CVD prevention beyond calcium score alone in an ever-growing, statin-eligible population.
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The liver is a critical pathophysiologic mediator of glycemic control and insulin sensitivity, linked to inflammation, obesity, subclinical cardiovascular disease and T2D [17e24]. Our results extend prior work [10, 25] by establishing the ability of CT markers of hepatic steatosis to effectively reclassify risk of incident T2D in a multi-ethnic, normoglycemic cohort over long-term follow-up beyond longitudinal changes in weight, waist circumference (an anthropometric marker of visceral adiposity), fasting glucose and incident statin prescription. Similarly, our results are in concert with a recent report from the MESA study suggesting poor reclassification metrics for CVD events with addition of liver attenuation to the Framingham risk score and coronary artery calcium score [26] . We additionally found that the distribution of hepatic attenuation does not vary based on coronary artery calcium score. In this context, our results define hepatic attenuation and coronary artery calcification as largely orthogonal, complementary biomarkers of metabolic and CVD risk, respectively, accessible in a single, noncontrast, low radiation dose CT examination currently accepted for risk assessment in CVD [27] .
These findings reach therapeutic relevance in their implications on surveillance and risk-benefit assessments for the increasing population of individuals eligible for statin therapy. As reported in a recent study from Pencina and colleagues from the National Health and Nutrition Examination Survey, the newly published ACC/AHA guidelines will extend statin prescriptions among individuals aged 60e75 years without established CVD to 77.3% of the population (for a 7.5% 10-year risk threshold) and up to 90% (for a 5% risk threshold; relative to 47.8% with previous guidelines) [1] . Given the goal to reduce incident CVD events through aggressive primary prevention therapy, the ACC/AHA has also advocated the use of coronary artery calcium scoring (a class IIa indication) to further refine risk in asymptomatic individuals at intermediate CVD risk (defined as 10e20% 10-year risk in prior guidelines) [27] . Indeed, recent studies from MESA suggest that individuals with a zero calcium score are at very low risk of CVD [15] , fueling suggestions that calcium score may be a method to focus therapy to those at highest risk. Regardless of which additional index is used, these considerations call for some additional, targeted risk stratification in primary prevention statin prescription.
There has been much controversy as to whether statin prescription per se increases diabetes risk or may be a marker of individuals at higher risk. Accordingly, effect size estimates that suggest that statin therapy imposes a higher risk for diabetes are highly variable, depending on study design. In a meta-analysis of published randomized statin trials (over 90,000 individuals), the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 hazard ratio for incident diabetes was 1.09, with treatment of 255 patients with statins for 4 years yielding 1 additional diabetes case [28] . On the other hand, in an observational study of over 25,000 individuals with propensity score matching (similar techniques as used in our study), statin use was associated with an odds ratio of 1.87 (95% CI 1.67e2.01) for incident diabetes [29] , similar as observed in MESA. Indeed, despite attempts at propensity matching to account for variation, inherent variability in populations between randomized controlled studies and observational cohorts may account for some of the heterogeneity in effect size: as observed here, individuals receiving statin therapy in MESA were at substantially higher cardiometabolic risk (Table 1) . Nevertheless, recent population-level Mendelian randomization studies suggest a potential mechanistic basis for statin-mediated HMG-CoA reductase inhibition on increased weight and incident type 2 diabetes (odds ratio 1.12) [30] . In the wake of the available evidence, our results do not endorse using imaging to withhold statin therapy: on the contrary, our results suggest that statin therapy is critical to disease prevention, but increased surveillance utilizing easily-accessed hepatic fat content obtained by CT at the time of coronary calcium scoring could be used to further risk stratify individuals for incident diabetes risk.
The results of our study should be viewed in the context of its design. As MESA is a prospective cohort study, we observed a significant imbalance in metabolic risk factors between those individuals who did and did not receive statin therapy in follow-up (Table 1) . Despite consistent results after propensity stratification or adjustment, the absolute measure of the association between statin therapy and incident T2D is therefore susceptible to residual confounding, and should be approached with caution (especially given lower effect sizes reported in previous randomized studies). The primary goal of our work was to examine the role of hepatic steatosis in balancing risk prediction (not estimating magnitude of statin-associated T2D). While we do not maintain that incident T2D and CVD are clinically equivalent outcomes, the imperative to improve risk stratification and early treatment by identifying those individuals at highest metabolic and CVD risk remains an important goal in disease prevention. Although we did not use data from MESA to derive statin-associated risk reduction for this cohort, we utilized estimates reported in a comprehensive meta-analysis that demonstrated consistent results across many high-quality randomized studies. Finally, while we did not specifically examine interactions between fatty liver and genetic variants in this study, we recognize this is an important area of future study.
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